南京诺惟生物

Nanjing Novel Biotech is a China-based biotechnology company specializing in the development of mRNA therapeutics and advanced lipid nanoparticle (LNP) delivery systems. Founded in 2021 and headquartered in Nanjing's Jiangbei New Area, the company focuses on overcoming technical barriers in nucleic acid drug delivery to create a robust pipeline of vaccines and treatments for infectious diseases and oncology. Their core technology platform aims to optimize the stability and tissue-specific targeting of mRNA payloads. The company is positioned as a platform-driven innovator in the rapidly growing field of genetic medicine in China. Nanjing Novel Biotech is currently in the pre-clinical stage, advancing several candidates through early-stage research and development.